Supreme Court Rules on Landmark Gene Patent Case
Beginning in 1995, in a genetics lab at the University of Pennsylvania, Haig Kazazian and his colleague Arupa Ganguly tested roughly 500 women per year for the breast-cancer-predicting genes BRCA1 and BRCA2.
In 1999, they received a "cease and desist" letter from Myriad Genetics, which had successfully patented the genes in 1998. In 2008, Kazazian and Ganguly became the first plaintiffs in the ACLU's case against Myriad and the U.S. Patent and Trademark Office.
The Supreme Court officially ruled on Association for Molecular Pathology v. Myriad Genetics, Inc. on June 13. Read about the ruling on Supreme Court's official blog.
Dr. Kazazian is now a professor at the Johns Hopkins University School of Medicine in the Institute of Genetic Medicine. He holds a gene patent of his own, but believes gene patenting should be limited to particular circumstances.
Dr. Kazazian: Comments on the Ruling
- How an End to Gene Patenting Impacts Patients -- and Science - WYPR, June 19, 2013
- The Gene Patenting Decision from a Plaintiff's Point of View - Science News, June 14, 2013
- After Supreme Court Ruling, Don't Count Out Gene Patenting Quite Yet - The Verge, June 14, 2013
- Ban on Patenting DNA Cheers Researchers - Baltimore Sun, June 13, 2013
- Johns Hopkins Researchers Capture Jumping Genes - February 4, 2011
- Burning to Do Research - McKusick-Nathans Institute of Genetic Medicine Newsletter, June 2009